{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-104743","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.544849+00:00","generated_at":"2026-06-10T07:44:48.511699+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TransCode closes $8.5M public offering; issues 16.9M shares/pre-funded warrants at $0.51","bullets":["Gross proceeds ~$8.5M from sale of 700K common shares and 16.2M pre-funded warrants at $0.51 per share/warrant, including partial over-allotment exercise.","Use of proceeds for clinical trials of lead candidate TTX-MC138 and working capital.","ThinkEquity sole book-runner; granted 45-day over-allotment option (partially exercised) plus 843K underwriter warrants at $0.6375 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-104743","json":"https://secwatch.observer/filing/0001104659-23-104743.json","markdown":"https://secwatch.observer/filing/0001104659-23-104743.md","text":"https://secwatch.observer/filing/0001104659-23-104743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/0001104659-23-104743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/tm2327131d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:44:48.511699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"350caf6f2dfddbe3d63ced599446d0c93364d77e","claim":"Transcode Therapeutics, Inc. entered into Underwriting Agreement with ThinkEquity LLC valued at approximately $8.5 million (effective 2023-09-25).","evidence_excerpt":"On September 25, 2023, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of (i) 700,000 shares (“Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase 16,163,000 shares of Common Stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/0001104659-23-104743-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"ThinkEquity LLC"},{"label":"Value","value":"approximately $8.5 million"},{"label":"Effective","value":"2023-09-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}